ホームページへ
4.6/5
TrustPilot

ページ3 - 最高の膠芽腫医師 - トップ83名の医師

50か国以上のトップ膠芽腫医師と価格を比較。こちらで最適なマッチングを見つけてください

3名のトップ専門家から見積もりを取得

ご要望と予算に基づいて最適な医師を厳選いたします

トップ医師

83

Turkey

レビュー

14000+

実際の患者より

個別化された治療計画を無料で取得し、最良のオプションを選択してください。コミットメント不要 · サービス料金なし

最初に表示:

Medical Park Antalya Hospital Complex
Mustafa Serkan Alemdar

Mustafa Serkan Alemdar

20年の経験
クリニックは認証済み
International Health Tourism Authorization Certificate
所在地: トルコ, アンタルヤ

Education and Specialization

  • 2006: Kocaeli University Faculty of Medicine
  • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
  • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

  • 2006 - 2008: Konya Derebucak District Hospital
  • 2009 - 2015: Akdeniz University Hospital
  • 2015: Antalya Kaş State Hospital
  • 2015 - 2016: İnönü University Faculty of Medicine
  • 2016 - 2021: Akdeniz University Hospital
  • 2021 - 2023: Antalya Training and Research Hospital
診察お問い合わせください
Medipol Bahçelievler Hospital
Nail Paksoy

Nail Paksoy

15年の経験
クリニックは認証済み
Joint Commission International
所在地: トルコ, イスタンブール
クリニック:
4.5
Medipol Bahçelievler Hospital


PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

 

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

 

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

  • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
  • Role: Subinvestigator

2. PFİZER

  • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
  • Role: Subinvestigator

3. RECITE - AMGEN

  • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
  • Role: Subinvestigator

4. NAVIGATE - BAYER

  • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
  • Role: Subinvestigator

5. RUBY - Tesaro (PRA)

  • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
  • Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

  • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
  • Role: Subinvestigator

7. ASTRA ZENECA

  • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
  • Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

  • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
  • Role: Subinvestigator
  •  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
  • Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
  • Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

  • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
  • Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

  • Authors: Paksoy, Nail, et al.
  • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

  • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
  • Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

  • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
  • Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

  • Authors: HAS SIMSEK, Duygu, et al.
  • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

  • Authors: FERHATOGLU, Ferhat, et al.
  • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

  • Authors: GÜRBÜZ, Mustafa, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

  • Authors: AY, Seval, et al.
  • Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

  • Authors: CIL, Ibrahim, et al.
  • Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

  • Authors: HIZAL, Mutlu, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
  • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
  • Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

  • Authors: DEMIR, Semra, et al.
  • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

  • Authors: ÖZDEMIR, Seçil Kepil, et al.
  • Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

  • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
  • Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

  • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
  • Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
  • Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
  • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

  • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
  • Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

  • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
  • Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

  • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
  • Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

  • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
  • Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

  • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
  • Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

 

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

  • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

  • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

  • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

  • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

  • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

  • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

  • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

  • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

 

 

パッケージ価格$12,000
Medipol Acibadem District Hospital
Atakan Topcu

Atakan Topcu

13年の経験
クリニックは認証済み
Joint Commission International
所在地: トルコ, イスタンブール

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

診察お問い合わせください
Pallas Clinic
Inta Jaunalksne

Inta Jaunalksne

49年の経験
所在地: ラトビア, ユールマラ
クリニック:
5.0
Pallas Clinic

医師は30年以上の経験を持つ免疫学者であり、免疫学の最先端分野であるウイルス療法を専門としています。 <\/p>

リガ医科大学を卒業し、内科でのインターンシップを修了しました。 <\/p>

現在、Pauls Stradins Clinical University Hospitalの臨床免疫学センターの責任者を務めています。<\/p>

診察お問い合わせください
Medipol Acibadem District Hospital
Ayse Irem Yasin

Ayse Irem Yasin

15年の経験
クリニックは認証済み
Joint Commission International
所在地: トルコ, イスタンブール

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

診察お問い合わせください
シファ・アル・オルマン国際腫瘍病院
Mohamed Mahmoud Abdelhakim

Mohamed Mahmoud Abdelhakim

26年の経験
クリニックは認証済み
ISO 9001:2015 Quality management systems
ISO 45001 (Occupational Health and Safety Management)
European Society for Medical Oncology
+1
所在地: エジプト, カイロ

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

パッケージ価格$150
Hadassah Medical Center
Tamar Jablonski-Perec

Tamar Jablonski-Perec

クリニックは認証済み
Nobel Peace Prize
World's Best Hospitals 2021 by Newsweek
World's Best Smart Hospitals 2021 by Newsweek
+1
所在地: イスラエル, エルサレム
クリニック:
4.4
Hadassah Medical Center

Tamar Jablonski-Perec is an oncologist at the Hadassah Medical Center who received her Doctor of Medical Sciences at the Hebrew University in Jerusalem and completed an internship at the renowned Sloan-Kettering Cancer Center in New York. Her key takeaways include:

  • Head of Institute of Oncology in 1994
  • Head of Breast Cancer Treatment Center in 1998
  • Professor of the Department of Oncology at the Hebrew University in 2006
  • Member of several international cancer communities
  • Awarded a scholarship from the Hadassah Medical School
診察お問い合わせください
シェバ医療センター
Yaacov Lawrence

Yaacov Lawrence

31年の経験
クリニックは認証済み
Best Maternity Hospitals 2021 by Newsweek
World's Best Smart Hospitals 2021 by Newsweek
World's Best Hospitals 2021 by Newsweek
+8
所在地: イスラエル, ラマト・ガン
クリニック:
5.0
シェバ医療センター

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

診察お問い合わせください
Samsung Medical Center
Do Hyun Nam

Do Hyun Nam

クリニックは認証済み
International Organization for Standardization
Korean Institute for Healthcare Accreditation
World's Best Hospitals 2021 by Newsweek
+3
所在地: 大韓民国, ソウル
クリニック:
4.5
Samsung Medical Center

Dr. Do Hyun Nam is considered one of the best pediatric and adult neurosurgeons in South Korea. He specializes in endoscopic surgeries, brain tumor removal, and radiosurgery. Treats both benign and malignant neoplasms.

診察お問い合わせください
Hospital Quiron Barcelona
Francesc Graus

Francesc Graus

44年の経験
クリニックは認証済み
Joint Commission International
所在地: スペイン, バルセロナ
クリニック:
4.4
Hospital Quiron Barcelona

グラウス博士の研究分野は、腫瘍随伴症候群です。彼はこれらの診断基準を初めて厳密に定義した専門家パネルを率いました。

彼の研究は、基礎腫瘍が脳神経系への自己免疫攻撃を引き起こすという免疫仮説を確認するうえで重要でした。彼が特定した抗体は現在、これらの症候群の診断に広く使用されています。

彼の臨床的専門知識には、神経膠腫と一次性脳リンパ腫の診断と管理、癌治療に由来する神経毒性が含まれます。最近では、免疫チェックポイント阻害剤による治療や造血幹細胞移植に関連する神経学的合併症に関心を持っています。
 

教育

1976年にバルセロナ自治大学で医学の学位を取得。

  • 1982年にバルセロナ自治大学で博士号を取得。
     
  • バルセロナでの神経内科のレジデンシーと、ニューヨーク、米国のメモリアル・スローン・ケタリングがんセンターでの神経腫瘍学フェローシップ。

履歴

  • 現在、IDIBAPSの名誉研究員。
  • 欧州神経腫瘍学会(EANO)の創設者および元会長
     
  • リヨン大学のホノリス・カウサ博士の称号。
  • 2018年までバルセロナの病院クリニックの神経科の主任
     
  • 病院クリニックに関連するアウグスティン・ピ・スニエール生物医学研究所(IDIBAPS)の神経免疫プログラムのコーディネーター。


 

診察お問い合わせください
İstinye University Liv Hospital Topkapı
Muhammed Mustafa Atci

Muhammed Mustafa Atci

15年の経験
所在地: トルコ, イスタンブール

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

診察お問い合わせください
シェバ医療センター
Raanan Berger

Raanan Berger

27年の経験
クリニックは認証済み
Best Maternity Hospitals 2021 by Newsweek
World's Best Smart Hospitals 2021 by Newsweek
World's Best Hospitals 2021 by Newsweek
+8
所在地: イスラエル, ラマト・ガン
クリニック:
5.0
シェバ医療センター

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

診察お問い合わせください
Before and after tummy tuck results at DR. IRERI ASTEINZA Clinic – flatter abdomen contour
Before and after tummy tuck results at DR. IRERI ASTEINZA Clinic, improved abdominal contour
Before and after tummy tuck results at DR. IRERI ASTEINZA Clinic – flatter abdomen
Before and after alarplasty results at DR. IRERI ASTEINZA Clinic, nose reshaping procedure
Before and after rhinoplasty results at DR. IRERI ASTEINZA Clinic, nose reshaping procedure
Before and after alarplasty results at DR. IRERI ASTEINZA Clinic, nose reshaping procedure
Before and after rhinoplasty results at DR. IRERI ASTEINZA Clinic, nose reshaping procedure
Before and after alarplasty results at DR. IRERI ASTEINZA Clinic, refined nostril shape
Before and after rhinoplasty results at DR. IRERI ASTEINZA Clinic, improved nose shape
Edmundo Pichardo

Edmundo Pichardo

39年の経験
クリニックは認証済み
American College of Obstetricians and Gynecologists
Consejo Mexicano de Cirugía Plástica, Estética y Reconstructiva
Joint Commission International
+18
所在地: メキシコ, メキシコシティ
クリニック:DR. IRERI ASTEINZA Clinic
診察お問い合わせください
San Raffaele
Pietro Mortini

Pietro Mortini

5 優秀3 レビュー
クリニックは認証済み
Scientific Institute for Research and Healthcare Accrediatation
World's Best Hospitals 2021 by Newsweek
所在地: イタリア, ミラノ
クリニック:
4.6
San Raffaele

サン・ラファエル病院の実験的脳神経外科ユニット長であるモルティーニ教授は、低侵襲の脳・脊椎外科手術を専門としています。

  • 脳神経外科における年以上の臨床経験
  • 精度向上のためのニューロナビゲーションおよびニューロマッピングの専門家
  • 組織再生法の特許取得
  • ジョージ・ワシントン大学客員教授
診察お問い合わせください
Expert Clinic
Manchenko Dina

Manchenko Dina

13年の経験
所在地: ウクライナ, ウージホロド
クリニック:
4.7
Expert Clinic
診察お問い合わせください
Emsey Hospital
Elnur Sahibov

Elnur Sahibov

10年の経験
クリニックは認証済み
The Baby-friendly Hospital Initiative (BFHI) by WHO and UNICEF
Turkish Medical Association
TEMOS International Healthcare Accreditation
+3
所在地: トルコ, イスタンブール
クリニック:
4.4
Emsey Hospital

Marmara University Faculty of Medicine, Department of Radiation Oncology Specialization training: 2012 -2016

Marmara University Faculty of Medicine (English) Undergraduate: 2004-2011

Sixteen Numbered Shirvan School (Azerbaijan) High School: 1998 -2004

診察お問い合わせください
DR. IRERI ASTEINZA Clinic
Oscar Arrieta

Oscar Arrieta

33年の経験
クリニックは認証済み
American College of Obstetricians and Gynecologists
Consejo Mexicano de Cirugía Plástica, Estética y Reconstructiva
Joint Commission International
+18
所在地: メキシコ, メキシコシティ
クリニック:DR. IRERI ASTEINZA Clinic
診察お問い合わせください
Medicana Sivas Hospital
Muhammed Gomec

Muhammed Gomec

17年の経験
所在地: トルコ, スィヴァス
クリニック:
5.0
Medicana Sivas Hospital
診察お問い合わせください
Private Koru Ankara Hospital
Emrah Eraslan

Emrah Eraslan

21年の経験
クリニックは認証済み
Turkish Medical Association
Joint Commission International
所在地: トルコ, アンカラ

Associate Professor Dr. Emrah Eraslan graduated from Ankara University Faculty of Medicine in 2005. From 2006 to 2011, he worked as a research assistant in the Department of Internal Medicine at Ankara University Faculty of Medicine and became an internal medicine specialist in 2011. Between 2011 and 2013, he worked as an internal medicine specialist and chief physician at Dr. Nafiz Körez Sincan State Hospital and Palu District State Hospital. From 2013 to 2016, he received medical oncology training at Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital and worked there until 2021. In 2023, he became an associate professor and contributed to his field with his publications throughout his career. He currently serves his patients at Koru Ankara Hospital. His medical interests include:

Breast Cancer

Prostate Cancer

Lung Cancer

Colorectal Cancer

Stomach Cancer

Ovarian Cancer

診察お問い合わせください

83名の医師のうち19名をご覧いただきました

海外のクリニックを選ぶことはストレスフルです。800,000名以上の患者をサポートしたBookimedは、お客様の懸念を理解しています。信頼できる医師、最高の価格品質オプション、複雑なケースの解決策を見つける方法を知っています。すべての段階でお客様をご案内いたします。

ヤン・マツィイフスキー

医療コーディネーターチーム責任者

4300+件以上の患者の旅をガイド

Bookimedで3

the USAの2691名の患者が今月当社を通じて医師を見つけました

完璧な医師マッチングを取得する方法

1

2分のクイズ

目標、予算、スケジュールをお聞かせください

2

人間のマッチング + AI

アルゴリズムがマッチングを見つけ、コーディネーターが適合性を確認します

3

オプション準備完了

価格、パッケージ、日程を比較。コーディネーターとチャット

選択肢に迷っていますか?

専属の Bookimedコーディネーターがお客様のニーズに合わせた完璧な外科医を見つけるお手伝いをします

  • すべての段階で24時間365日サポート
  • 医師とのマッチングサポートとクリニックとの全てのコミュニケーションを処理
  • 旅行、宿泊、送迎を調整します

治療をガイド

医療訓練を受けた専属コーディネーター

Peguy Beaugris
Tetyana Hyrych
Zekra Eldeeb
Victoria Olayinka
Iryna Sydorchuk
Tetiana Ihnatiuk

適切な医師とクリニックの選び方:内部者のヒント

医師やクリニックを選ぶ際は、これらの重要なポイントを覚えておいてください:
資格を確認
ISAPS、JCI、または関連医学会などの機関からの認証を確認してください
成功率を確認
お客様の特定治療に豊富な経験と実績のある医師をお選びください
患者レビューを読む
実際の患者様のBookimedレビューをご覧になり、体験について学んでください
効果的なコミュニケーションの確保
円滑な治療のため言語サポートを提供するクリニックを選んでください。
サービスについて質問
隠れた費用を避けるため、価格に宿泊、現地送迎、アフターケアなどのサービスが含まれているかご確認ください

Bookimed洞察:世界のトップ膠芽腫専門家(2026)

Bookimedは膠芽腫治療のグローバルリクエスト621件を調整し、83名のトップ評価専門家と協力しています。この表の医師は国際的資格、臨床専門知識、患者の結果に基づいて選ばれています。2026年グローバルランキングは実際の患者ケースとパートナークリニックの現行プログラムからの検証済みデータを使用して形成されています
順位医師経験適合する方特色クリニックと所在地診察
#1低侵襲脳外科手術サン・ラファエル病院の実験的神経外科ユニットを主導し、神経ナビゲーションを用いたより低侵襲な手技の先駆者である。組織再生法に関する特許を保有している。
イタリア
お問い合わせください